person
Nicolas A.
- Country
- France
- Department
- Pediatric hematology immunology oncology
Research Overview
assignment
32
Clinical Trials ·
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- Phase 1b/2 Study of Ifinatamab Deruxtecan in Pediatric Patients with Relapsed or Refractory Solid Tumors (Neuroblastoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma)
- Phase II Evaluation of RO7435846 in Combination with Multiple Agents for Biomarker-Positive Advanced or Metastatic Solid Tumors
location_city
3
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
158
Sites with multiple studies
Has run more than one trial at 158 of 272 partner sites.
Specializations
Pediatric Oncology Focus
Specializes in treating advanced solid tumors and central nervous system tumors in children and young adults, with particular emphasis on innovative therapeutic approaches.
- Refractory and relapsed solid tumors
- Medulloblastoma and ependymoma
- High-grade gliomas
Therapeutic Expertise
Focuses on targeted therapies and immunotherapy combinations for pediatric cancers, including novel treatment approaches for rare and aggressive tumors.
- Metronomic chemotherapy
- Molecular targeted agents
- Immunotherapy protocols
Specialized Treatment Areas
Develops treatment protocols for rare pediatric cancers and molecular-driven therapies for specific tumor types.
- ALK fusion-positive tumors
- Ewing sarcoma
- Atypical teratoid/rhabdoid tumors
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.